Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859339 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00859339 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 9 participants.
The verdict
NCT00859339, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- PROCEDURE Radical Cystectomy
- DRUG Sunitinib Malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859339
The ClinicalTrials.gov registry entry for NCT00859339 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noah Hahn, M.D., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00859339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859339 about?
NCT00859339 is a clinical study titled "Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC". This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
What is the current status of trial NCT00859339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00859339?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Radical Cystectomy (PROCEDURE), Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT00859339?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.